What can be expected from the cholesterol-lowering drugs market? Which areas are going to grow at the fastest rates? This Visiongain report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there.
Our 199-page report provides 153 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.
Forecasts from 2015-2025 and other analyses show you commercial prospects Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter’s Five Forces analysis) and commercial developments.
See revenue forecasts for the leading submarkets and indications How will submarkets perform to 2025? Our study forecasts revenues in the following cholesterol-lowering drugs submarkets and products: • Statins and Fixed-Dose Combinations – Crestor – Lipitor – Livalo – Lescol/Lescol XL – Zocor – Vytorin – Caduet – Other Statins and Fixed-Dose Combinations (grouped forecast) • Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs – Zetia – Welchol – Tricor – Other cholesterol-lowering drugs (grouped forecast) • PCSK9 Inhibitors – Praluent – Repatha – RN316 – Other PCSK9 Inhibitors (grouped forecast) • Novel Cholesterol-Lowering Drugs – Juxtapid – Kynamro – MK-0859 – Other novel cholesterol-lowering drugs (grouped forecast)
See revenue forecasts for the leading international markets How will leading national markets perform to 2025? Our study forecasts revenues in national markets including products, including: • US • Japan • Germany • France • Italy • Spain • UK • China • Brazil • Russia • India
Leading companies and potential for market growth Overall revenue for the cholesterol-lowering drugs market will reach $24.63bn in 2019, our work forecasts. We predict strong revenue growth through to 2025. Shifts in diets and lifestyles will contribute to rising levels of high cholesterol, while highly disruptive new treatments will revitalise the market
Our work analyses the key companies in the market. See Visiongain’s analysis of 9 leading companies, including these: • AstraZeneca • Merck • Pfizer • Kowa • Daiichi Sankyo • Abbvie • Novartis • Sanofi • Amgen
A company profile gives you the following information where available: • Discussion of a company’s activities and outlook • Analysis of products currently on the market as well as pipeline products • Company news relevant to the market
Discover capabilities, progress, and commercial prospects, helping you stay ahead.
What issues will affect Cholesterol-Lowering Drugs industry? Our new report discusses issues and events affecting the cholesterol-lowering drugs market. You will find discussions, including qualitative analyses: • Highly disruptive treatments entering the market • Increasing potential in both established and emerging markets
You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.
How the Cholesterol-Lowering Drugs Market Forecast 2015-2025 report helps you In summary, our 199-page report gives you the following knowledge: • Revenue forecasts to 2025 for the Cholesterol-Lowering Drugs market – discover the industry’s prospects, finding promising places for investments and revenues • Revenue forecasts to 2025 for submarkets in each – statins and fixed-dose combinations, absorption inhibitors, ion-exchange resins fibrates, PCSK9 inhibitors and novel drugs • Revenue forecasts to 2025 for the leading regional markets – US, Japan, EU5 and BRIC • Assessment of 9 leading companies – analysis of cholesterol-lowering products, revenue, news and upcoming product releases • Discussion of what stimulates and restrains companies and the market • Prospects for established firms and those seeking to enter the market
You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain’s study is for everybody needing commercial analyses for the cholesterol-lowering drugs market and leading companies. You will find data, trends and predictions. Please order our report now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Global Cholesterol-Lowering Drugs Market Overview 1.2 Global Cholesterol-Lowering Drugs Market Segmentation 1.3 Why You Should Read This Report 1.4 How This Report Delivers 1.5 Key Questions Answered by This Analytical Report 1.6 Who is This Report For? 1.7 Methodology 1.8 Frequently Asked Questions (FAQ) 1.9 Associated Visiongain Reports 1.10 About Visiongain
2. Introduction to Cholesterol-Lowering Drugs 2.1 The Pharmaceutical Industry: A Brief Overview 2.2 Cholesterol: An Essential Lipid 2.3 The Functions of Cholesterol 2.4 Metabolism and Circulation of Cholesterol 2.5 The Role of Cholesterol in Heart Disease 2.6 The Role of Cholesterol in Heart Disease: The Orthodoxy 2.6.1 The IMPROVE-IT Study 2.7 The Role of Cholesterol in Heart Disease: The Controversy 2.8 Raising HDL Cholesterol: A Worthwhile Aim? 2.9 Causes of Hypercholesterolaemia 2.9.1 Atherosclerosis 2.9.2 Dyslipidaemia, Hyperlipidaemia and Hyperlipoproteinaemia 2.9.3 Familial Hypercholesterolaemia 2.10 Treatment of Hypercholesterolaemia 2.10.1 UK Treatment Guidelines for Hypercholesterolaemia 2.10.2 US Treatment Guidelines for Hypercholesterolaemia 2.10.3 Lifestyle Changes 2.10.4 Drugs to Lower Cholesterol 2.10.5 Other Therapeutic Approaches 2.10.5.1 Partial Ileal Bypass: An Outdated Surgical Treatment 2.10.5.2 LDL Apheresis: Directly Removing Cholesterol 2.10.5.3 Liver Transplantation for Familial Hypercholesterolaemia 2.11 Classification of Cholesterol-Lowering Drugs 2.11.1 Statins 2.11.2 Selective Cholesterol Absorption Inhibitors 2.11.3 Ion Exchange Resins 2.11.4 Fibrates 2.11.5 Other Cholesterol-Lowering Drugs 2.11.6 Novel Cholesterol-Lowering Drugs 2.11.7 PCSK9 Inhibitors 2.12 Phases of Clinical Trials 2.13 Scope of This Report 2.13.1 Products Excluded from This Report 2.14 Currency Exchange Rates in This Report
3. Cholesterol-Lowering Drugs: World Market 2015-2025 3.1 The World Cholesterol-Lowering Drugs Market in 2014 3.1.1 Leading Cholesterol-Lowering Drugs Products 3.1.2 Leading Companies in the Cholesterol-Lowering Drugs Market 3.2 World Cholesterol-Lowering Drugs Market: Sales Forecast 2015-2025 3.3 Cholesterol-Lowering Drugs Market Segments: Sales Forecasts 2015-2025 3.3.1 Cholesterol-Lowering Drugs Market Segmentation 3.4 Changing Market Shares by Segment 2015-2025 3.4.1 World Cholesterol-Lowering Drugs Market: Drivers and Restraints 2015-2025
4. Leading National Markets, 2015-2025 4.1 Regional Breakdown of the World Cholesterol-Lowering Drugs Market 4.1.1 World Cholesterol-Lowering Drugs Market: Regional Forecast 2015-2025 4.1.2 How Will Regional Market Shares Change to 2025? 4.2 National Breakdown of the World Cholesterol-Lowering Drugs Market 4.2.1 World Cholesterol-Lowering Drugs Market: National Markets Forecast 2015-2025 4.2.2 How Will National Market Shares Change to 2025? 4.3 The US Cholesterol-Lowering Drugs Market 2015-2025 4.3.1 US Cholesterol-Lowering Drug Market Forecast 2015-2025 4.3.2 US Cholesterol-Lowering Drugs Market: Drivers and Restraints 4.3.2.1 High Prevalence of High Cholesterol in US 4.4 The Cholesterol-Lowering Drugs Market in the Five Leading European National Markets to 2025 4.4.1 EU5 Cholesterol-Lowering Drugs Market: Drivers and Restraints 4.4.2 The Cholesterol-Lowering Drugs Market in Germany to 2025 4.4.2.1 German Cholesterol-Lowering Drugs Market: Trends and Developments 4.4.3 The Cholesterol-Lowering Drugs Market in France to 2025 4.4.3.1 French Cholesterol-Lowering Drugs Market: Trends and Developments 4.4.4 The Cholesterol-Lowering Drugs Market in the UK to 2025 4.4.4.1 UK Cholesterol-Lowering Drugs Market: Trends and Developments 4.4.5 The Cholesterol-Lowering Drugs Market in Italy to 2025 4.4.5.1 Italian Cholesterol-Lowering Drugs Market: Trends and Developments 4.4.6 The Cholesterol-Lowering Drugs Market in Spain to 2025 4.4.6.1 Spanish Cholesterol-Lowering Drugs Market: Trends and Developments 4.5 The Cholesterol-Lowering Drugs Market in the BRIC National Markets to 2025 4.5.1 BRIC Cholesterol-Lowering Drugs Market: Drivers and Restraints 4.5.2 The Cholesterol-Lowering Drugs Market in China to 2025 4.5.2.1 Chinese Cholesterol-Lowering Drugs Market: Trends and Developments 4.5.2.1.1 Economic Challenges 4.5.2.1.2 Expansion of Healthcare Coverage and Reimbursement 4.5.3 The Cholesterol-Lowering Drugs Market in Brazil to 2025 4.5.3.1 Brazilian Cholesterol-Lowering Drugs Market: Trends and Developments 4.5.4 The Cholesterol-Lowering Drugs Market in Russia to 2025 4.5.4.1 Russian Cholesterol-Lowering Drugs Market: Trends and Developments 4.5.4.1.1 Lower Oil Prices 4.5.4.1.2 No Embargo on Foreign Drugs 4.5.5 The Cholesterol-Lowering Drugs Market in India to 2025 4.5.5.1 Indian Cholesterol-Lowering Drugs Market: Trends and Developments 4.5.5.1.1 Drug Price Control Order 2014 4.5.5.1.2 Expansion of Healthcare Provision 4.6 The Cholesterol-Lowering Drugs Market in Japan to 2025 4.6.1 Japanese Cholesterol-Lowering Drugs Market: Trends and Developments 4.6.1.1 Generic Penetration to Reach 60% by 2018? 4.6.1.2 Japanese Pharmaceutical Industry Regulatory Reform
6. Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs: Market and Pipeline 2015-2025 6.1 Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs: Overview 6.2 The Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Market in 2014 6.3 Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs: Market Forecast 2015-2025 6.4 How Will Market Shares of Products Change to 2025? 6.5 Zetia (Ezetimibe, Merck) 6.5.1 The ENHANCE Study: No Additional Benefit 6.5.2 The IMPROVE-IT Study: Reduction in Cardiovascular Risk 6.5.3 Zetia: Sales Forecast 2015-2025 6.6 Welchol (Colesevelam, Daiichi Sankyo) 6.6.1 Threat of Imminent Generic Competition for Welchol 6.6.2 Welchol: Sales Forecast 2015-2025 6.7 Tricor (Fenofibrate, AbbVie) 6.7.1 Generic Erosion of Tricor Sales 6.7.2 Tricor: Sales Forecast 2015-2025
7. PCSK9 Inhibitors: Market and Pipeline 2015-2025 7.1 PCSK9 Inhibitors: The Next Blockbuster Drug Class? 7.2 PCSK9 in Clinical Trials 7.3 PCSK9 Inhibitors and Statins 7.4 PCSK9 Inhibitors: Market Forecast 2015-2025 7.5 How Will Market Shares of Products Change to 2025? 7.6 PCSK9 Inhibitors: Pipeline Analysis 2015-2025 7.7 Praluent (Alirocumab, Sanofi/Regeneron) 7.7.1 Praluent: Sales Forecast 2015-2025 7.8 Repatha (Evolocumab, Amgen) 7.8.1 GAUSS-2 7.8.2 RUTHERFORD-2 7.8.3 LAPLACE-2 7.8.4 Repatha: Sales Forecast 2015-2025 7.9 RN316 (Bococizumab, Pfizer) 7.9.1 RN316: Sales Forecast 2015-2025 7.10 Oral PCSK9 Inhibitor (Pfizer) 7.11 PF-06427878 (Pfizer) 7.12 PCSK9 Vaccine (Pfizer) 7.13 SX-PCK9 (Serometrix) 7.14 Discontinued Pipeline Products 7.14.1 BMS-962476 (Adnectin, Bristol-Myers Squibb) 7.14.2 LY3015014 (Eli Lilly)
9. Leading Companies in the Cholesterol-Lowering Drugs Market 9.1 Leading Cholesterol-Lowering Drugs Manufacturers in 2014 9.1.1 Leading Companies: Market Forecast 2015-2025 9.1.2 How Will Leading Companies’ Market Shares Change to 2025? 9.2 AstraZeneca 9.2.1 AstraZeneca: Cholesterol-Lowering Drugs 9.2.2 AstraZeneca: Sales Forecast 2015-2025 9.2.3 AstraZeneca: Recent Developments 9.2.3.1 Cholesterol Awareness Initiative in America 9.2.3.2 AstraZeneca Rejects Pfizer Takeover Bid 9.3 Merck 9.3.1 Merck: Cholesterol-Lowering Drugs 9.3.2 Merck: Sales Forecast 2015-2025 9.3.3 Merck: Recent Developments 9.3.3.1 Bayer Acquires Merck’s Consumer Health Business 9.3.3.2 Study Shows Lower LDL Levels Are More Beneficial 9.4 Pfizer 9.4.1 Pfizer: Cholesterol-Lowering Drugs 9.4.2 Pfizer: Sales Forecast 2015-2025 9.4.3 Pfizer: Recent Developments 9.4.3.1 Pfizer Ends Over-The-Counter Lipitor Program 9.4.3.2 Development of Oral PCSK9 Inhibitor 9.5 Kowa 9.5.1 Kowa: Cholesterol-Lowering Drugs 9.5.2 Kowa: Sales Forecast 2015-2025 9.5.3 Kowa: Recent Developments 9.5.3.1 Development of K-312 9.5.3.2 Development of K-887 9.6 Daiichi Sankyo 9.6.1 Daiichi Sankyo: Cholesterol-Lowering Drugs 9.6.2 Daiichi Sankyo: Sales Forecast 2015-2025 9.6.3 Daiichi Sankyo: Recent Developments 9.6.3.1 Staff Reduction at US Operation 9.7 AbbVie 9.7.1 AbbVie: Cholesterol-Lowering Drugs 9.7.2 AbbVie: Sales Forecast 2015-2025 9.7.3 AbbVie: Recent Developments 9.7.3.1 Possible Marketing Cost Reductions 9.8 Novartis 9.8.1 Novartis: Cholesterol-Lowering Drugs 9.8.2 Novartis: Sales Forecast 2015-2025 9.9 Sanofi 9.9.1 Sanofi: Cholesterol-Lowering Drugs 9.9.2 Sanofi: Sales Forecast 2015-2025 9.9.3 Sanofi: Recent Developments 9.9.3.1 Purchase of Priority Review Voucher from BioMarin Pharmaceuticals 9.10 Amgen 9.10.1 Amgen: Cholesterol-Lowering Drugs 9.10.2 Amgen: Sales Forecast 2015-2025 9.10.3 Amgen: Recent Developments 9.10.3.1 Amgen Sues Sanofi and Regeneron To Block Praluent
10. Qualitative Analysis of the Cholesterol-Lowering Drugs Market 2015-2025 10.1 SWOT Analysis of the Cholesterol-Lowering Drugs Market 10.2 Strengths 10.2.1 Strong Pipeline 10.2.2 High Profile Encouraging Healthcare Provision 10.3 Weaknesses 10.3.1 Increasing Generic Penetration 10.3.2 Approved Indications Limited for New Products 10.4 Opportunities 10.4.1 Increasing Prevalence in Emerging Markets 10.4.2 Possible Additional Indications 10.5 Threats 10.5.1 Patent Expiry 10.5.2 Cost-Containment 10.6 Porter’s Five Forces Analysis of the Cholesterol-Lowering Drugs Market 10.6.1 Rivalry among Competitors [High] 10.6.2 Threat of New Entrants [Medium] 10.6.3 Power of Suppliers [Low] 10.6.4 Power of Buyers [Medium] 10.6.5 Threat of Substitutes [High]
11. Conclusions 11.1 The World Cholesterol-Lowering Drugs Market: 2014-2015 11.2 The World Cholesterol-Lowering Drugs Market Forecast: 2014-2025
12. Glossary
List of Tables Table 1.1 Leading National Cholesterol-Lowering Drugs Market Forecast 2015 ($m, AGR%) Table 2.1 Clinical Trial Phases Table 2.2 Currency Exchange Rates, 2014 Table 3.1 Top 10 Cholesterol-Lowering Drugs: Revenue ($m) and Market Share (%), 2014 Table 3.2 World Cholesterol-Lowering Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2025 Table 3.3 World Cholesterol-Lowering Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Drug Class, 2014-2025 Table 3.4 Market Shares (%) of Cholesterol-Lowering Drug Market Segments, 2014, 2019 and 2025 Table 4.1 World Cholesterol-Lowering Drugs Market: Revenues ($m) and Market Shares (%) by Region, 2014 Table 4.2 World Cholesterol-Lowering Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Region, 2014-2025 Table 4.3 Market Shares (%) of Leading Cholesterol-Lowering Drugs Market, 2014, 2019 and 2025 Table 4.4 World Cholesterol-Lowering Drugs Market: Revenues ($m), and Market Shares (%) by National Market, 2014 Table 4.5 World Cholesterol-Lowering Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by National Market, 2014-2025 Table 4.6 World Cholesterol-Lowering Drugs Market: Market Shares (%) by National Market, 2014 Table 4.7 US Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025 Table 4.8 EU5 Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025 Table 4.9 German Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025 Table 4.10 French Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025 Table 4.11 UK Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025 Table 4.12 Italian Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025 Table 4.13 Spanish Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025 Table 4.14 BRIC Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025 Table 4.15 Chinese Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025 Table 4.16 Brazilian Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025 Table 4.17 Russian Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025 Table 4.18 Indian Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025 Table 4.19 Japanese Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025 Table 5.1 Leading Statins and Fixed-Dose Combinations: Revenue ($m) and Market Shares (%), 2014 Table 5.2 Statins and Fixed-Dose Combinations Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025 Table 5.3 Statins and Fixed-Dose Combinations Market: Market Shares (%) by Drug, 2014, 2019 and 2025 Table 5.4 AstraZeneca/Shionogi: Crestor Revenue ($m), AGR (%) and CAGR (%), 2009-2014 Table 5.5 AstraZeneca/Shionogi: Crestor Revenue ($m), AGR (%) and CAGR (%), 2014-2025 Table 5.6 Pfizer: Lipitor Revenue ($m), AGR (%) and CAGR (%), 2009-2014 Table 5.7 Pfizer: Lipitor Revenue ($m), AGR (%) and CAGR (%), 2014-2025 Table 5.8 Kowa: Livalo Revenue ($m), AGR (%) and CAGR (%), 2014-2025 Table 5.9 Novartis: Lescol/Lescol XL Revenue ($m), AGR (%) and CAGR (%), 2014-2025 Table 5.10 Merck: Zocor Revenue ($m), AGR (%) and CAGR (%), 2014-2025 Table 5.11 Merck: Vytorin Revenue ($m), AGR (%) and CAGR (%), 2014-2025 Table 5.12 Pfizer: Caduet Revenue ($m), AGR (%) and CAGR (%), 2014-2025 Table 6.1 Leading Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs: Revenue ($m) and Market Shares (%), 2014 Table 6.2 Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025 Table 6.3 Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Market: Market Shares (%) by Drug, 2014, 2019 and 2025 Table 6.4 Merck: Zetia Revenue ($m), AGR (%) and CAGR (%), 2014-2025 Table 6.5 Daiichi Sankyo: Welchol Revenue ($m), AGR (%) and CAGR (%), 2014-2025 Table 6.6 AbbVie: Tricor Revenue ($m), AGR (%) and CAGR (%), 2014-2025 Table 7.1 PCSK9 Inhibitors Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025 Table 7.2 PCSK9 Inhibitors Market: Market Shares (%) by Drug, 2015, 2019 and 2025 Table 7.3 Sanofi/Regeneron: Praluent Revenue ($m), AGR (%) and CAGR (%), 2014-2025 Table 7.4 Amgen: Repatha Revenue ($m), AGR (%) and CAGR (%), 2014-2025 Table 7.5 Pfizer: RN316 (Bococizumab) Revenue ($m), AGR (%) and CAGR (%), 2014-2025 Table 8.1 Novel Cholesterol-Lowering Drugs: Revenue ($m) and Market Shares (%), 2014 Table 8.2 Novel Cholesterol-Lowering Drugs Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025 Table 8.3 Novel Cholesterol-Lowering Drugs Market: Market Shares (%) by Drug, 2014, 2019 and 2025 Table 8.4 Merck: MK-0859 (Anacetrapib) Revenue ($m), AGR (%) and CAGR (%), 2014-2025 Table 8.5 Aegerion Pharmaceuticals: Juxtapid (Lomitapide) Revenue ($m), AGR (%) and CAGR (%), 2014-2025 Table 8.6 Isis Pharmaceuticals/Sanofi: Kynamro (Mipomersen) Revenue ($m), AGR (%) and CAGR (%), 2014-2025 Table 9.1 Leading Cholesterol-Lowering Drugs Manufacturers: Cholesterol-Lowering Drugs Revenue ($m), Market Share (%), 2014 Table 9.2 Leading Cholesterol-Lowering Drug Manufacturers: Revenue ($m), AGR (%) and CAGR (%), 2014-2025 Table 9.3 Leading Cholesterol-Lowering Drug Manufacturers: Revenue ($m) and Market Shares (%), 2019 and 2025 Table 9.4 AstraZeneca: Cholesterol-Lowering Drugs: Revenue ($m), AGR (%) and CAGR (%) by Drug, 2014-2025 Table 9.5 Merck: Cholesterol-Lowering Drugs: Revenue ($m), AGR (%) and CAGR (%) by Drug, 2014-2025 Table 9.6 Pfizer: Cholesterol-Lowering Drugs: Revenue ($m), AGR (%) and CAGR (%) by Drug, 2014-2025 Table 9.7 Kowa: Cholesterol-Lowering Drugs: Revenue ($m), AGR (%) and CAGR (%) by Drug, 2014-2025 Table 9.8 Daiichi Sankyo: Cholesterol-Lowering Drugs: Revenue ($m), AGR (%) and CAGR (%) by Drug, 2014-2025 Table 9.9 AbbVie: Cholesterol-Lowering Drugs: Revenue ($m), AGR (%) and CAGR (%) by Drug, 2014-2025 Table 9.10 Novartis: Cholesterol-Lowering Drugs: Revenue ($m), AGR (%) and CAGR (%) by Drug, 2014-2025 Table 9.11 Sanofi: Cholesterol-Lowering Drugs: Revenue ($m), AGR (%) and CAGR (%) by Drug, 2014-2025 Table 9.12 Amgen: Cholesterol-Lowering Drugs: Revenue ($m), AGR (%) and CAGR (%) by Drug, 2014-2025 Table 10.1 SWOT Analysis of the Cholesterol-Lowering Drugs Market, 2015-2025 Table 11.1 World Cholesterol-Lowering Drug Market Regions: Revenues ($m), 2014 and 2015 Table 11.2 World Cholesterol-Lowering Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2025
List of Figures Figure 1.1 Global Cholesterol-Lowering Drugs Market Segmentation Overview, 2015 Figure 2.1 Chemical Structure of Cholesterol, 2015 Figure 3.1 Top 10 Cholesterol-Lowering Drugs: Market Share (%), 2014 Figure 3.2 World Cholesterol-Lowering Drugs Market Forecast: Revenue ($m) and AGR (%), 2014-2025 Figure 3.3 World Cholesterol-Lowering Drugs Market Forecast: Revenue ($m) by Drug Class, 2014-2025 Figure 3.4 Market Shares (%) of Cholesterol-Lowering Drug Market Segments, 2019 Figure 3.5 Market Shares (%) of Cholesterol-Lowering Drug Market Segments, 2025 Figure 3.6 Global Cholesterol-Lowering Drugs Market: Drivers and Restraints, 2015-2025 Figure 4.1 World Cholesterol-Lowering Drugs Market: Revenues ($m) by Region, 2014 Figure 4.2 World Cholesterol-Lowering Drugs Market: Market Shares (%) by Region, 2014 Figure 4.3 World Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) by Region, 2014-2025 Figure 4.4 World Cholesterol-Lowering Drugs Market: Market Shares (%) by Region, 2019 Figure 4.5 World Cholesterol-Lowering Drugs Market: Market Shares (%) by Region, 2025 Figure 4.6 World Cholesterol-Lowering Drugs Market: Revenues ($m) by National Market, 2014 Figure 4.7 World Cholesterol-Lowering Drugs Market: Market Shares (%) by National Market, 2014 Figure 4.8 World Cholesterol-Lowering Drugs Market: Market Shares (%) by National Market, 2019 Figure 4.9 World Cholesterol-Lowering Drugs Market: Market Shares (%) by National Market, 2025 Figure 4.10 US Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025 Figure 4.11 EU5 Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025 Figure 4.12 EU5 Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), 2014-2025 Figure 4.13 German Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025 Figure 4.14 French Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025 Figure 4.15 UK Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025 Figure 4.16 Italian Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025 Figure 4.17 Spanish Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025 Figure 4.18 BRIC Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025 Figure 4.19 BRIC Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), 2014-2025 Figure 4.20 Chinese Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025 Figure 4.21 Brazilian Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025 Figure 4.22 Russia Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025 Figure 4.23 Indian Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025 Figure 4.24 Japanese Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025 Figure 5.1 Statins and Fixed-Dose Combinations Market: Market Shares (%), 2014 Figure 5.2 Statins and Fixed-Dose Combinations Market Forecast: Revenue ($m) and AGR (%), 2014-2025 Figure 5.3 Statins and Fixed-Dose Combinations Market: Market Shares (%), 2019 Figure 5.4 Statins and Fixed-Dose Combinations Market: Market Shares (%), 2025 Figure 5.5 AstraZeneca/Shionogi: Crestor Revenue ($m) and AGR (%), 2009-2014 Figure 5.6 AstraZeneca/Shionogi: Crestor Revenue ($m) and AGR (%), 2014-2025 Figure 5.7 Pfizer: Lipitor Revenue ($m) and AGR (%), 2009-2014 Figure 5.8 Pfizer: Lipitor Revenue ($m) and AGR (%), 2014-2025 Figure 5.9 Kowa: Livalo Revenue ($m) and AGR (%), 2014-2025 Figure 5.10 Novartis: Lescol/Lescol XL Revenue ($m) and AGR (%), 2014-2025 Figure 5.11 Merck: Zocor Revenue ($m) and AGR (%), 2014-2025 Figure 5.12 Merck: Vytorin Revenue ($m) and AGR (%), 2014-2025 Figure 5.13 Pfizer: Caduet Revenue ($m) and AGR (%), 2014-2025 Figure 6.1 Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs: Market Shares (%), 2014 Figure 6.2 Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Forecast: Revenue ($m) and AGR (%), 2014-2025 Figure 6.3 Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Market: Market Shares (%), 2019 Figure 6.4 Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Market: Market Shares (%), 2025 Figure 6.5 Merck: Zetia Revenue ($m) and AGR (%), 2014-2025 Figure 6.6 Daiichi Sankyo: Welchol Revenue ($m) and AGR (%), 2014-2025 Figure 6.7 AbbVie: Tricor Revenue ($m) and AGR (%), 2014-2025 Figure 7.1 PCSK9 Inhibitors Forecast: Revenue ($m) and AGR (%), 2014-2025 Figure 7.2 PCSK9 Inhibitors Market: Market Shares (%), 2015 Figure 7.3 PCSK9 Inhibitors Market: Market Shares (%), 2019 Figure 7.4 PCSK9 Inhibitors Market: Market Shares (%), 2025 Figure 7.5 Sanofi/Regeneron: Praluent Revenue ($m) and AGR (%), 2014-2025 Figure 7.6 Amgen: Repatha Revenue ($m) and AGR (%), 2014-2025 Figure 7.7 Pfizer: RN316 (Bococizumab) Revenue ($m) and AGR (%), 2014-2025 Figure 8.1 Novel Cholesterol-Lowering Drugs: Market Shares (%), 2014 Figure 8.2 Novel Cholesterol-Lowering Drugs Forecast: Revenue ($m) and AGR (%), 2014-2025 Figure 8.3 Novel Cholesterol-Lowering Drugs Market: Market Shares (%), 2019 Figure 8.4 Novel Cholesterol-Lowering Drugs Market: Market Shares (%), 2025 Figure 8.5 Merck: MK-0859 (Anacetrapib) Revenue ($m) and AGR (%), 2014-2025 Figure 8.6 Aegerion Pharmaceuticals: Juxtapid (Lomitapide) Revenue ($m) and AGR (%), 2014-2025 Figure 8.7 Isis Pharmaceuticals/Sanofi: Kynamro (Mipomersen) Revenue ($m) and AGR (%), 2014-2025 Figure 9.1 Leading Cholesterol-Lowering Drug Manufacturers: Revenue ($m), 2014 Figure 9.2 Leading Cholesterol-Lowering Drug Manufacturers: Market Shares (%), 2014 Figure 9.3 Leading Cholesterol-Lowering Drug Manufacturers: Revenues ($m), 2019 Figure 9.4 Leading Cholesterol-Lowering Drug Manufacturers: Market Shares (%), 2019 Figure 9.5 Leading Cholesterol-Lowering Drug Manufacturers: Revenues ($m), 2025 Figure 9.6 Leading Cholesterol-Lowering Drug Manufacturers: Market Shares (%), 2025 Figure 9.7 AstraZeneca: Cholesterol-Lowering Drugs: Revenue ($m) and AGR (%) 2014-2025 Figure 9.8 Merck: Cholesterol-Lowering Drugs: Revenue ($m) and AGR (%) 2014-2025 Figure 9.9 Pfizer: Cholesterol-Lowering Drugs: Revenue ($m) and AGR (%) 2014-2025 Figure 9.10 Kowa: Cholesterol-Lowering Drugs: Revenue ($m) and AGR (%) 2014-2025 Figure 9.11 Daiichi Sankyo: Cholesterol-Lowering Drugs: Revenue ($m) and AGR (%) 2014-2025 Figure 9.12 AbbVie: Cholesterol-Lowering Drugs: Revenue ($m) and AGR (%) 2014-2025 Figure 9.13 Novartis: Cholesterol-Lowering Drugs: Revenue ($m) and AGR (%) 2014-2025 Figure 9.14 Sanofi: Cholesterol-Lowering Drugs: Revenue ($m) and AGR (%) 2014-2025 Figure 9.15 Amgen: Cholesterol-Lowering Drugs: Revenue ($m) and AGR (%) 2014-2025 Figure 10.1 Porter’s Five Forces Analysis of the Cholesterol-Lowering Drugs Market, 2015-2025 Figure 11.1 World Cholesterol-Lowering Drugs Market Forecast: Revenue ($m), by Segment, 2014-2025
Organisations Mentioned in the Report American College of Cardiology American Heart Association Department of Pharmaceuticals (India) European Society of Cardiology National Health Service National Heart, Lung, and Blood Institute United Nations Department of Economic and Social Affairs US Dietary Guidelines Advisory Committee US Food and Drug Administration World Health Organization
Download sample pages
Complete the form below to download your free sample pages for Cholesterol-Lowering Drugs Market Forecast 2015-2025
Download sample pages
Complete the form below to download your free sample pages for Cholesterol-Lowering Drugs Market Forecast 2015-2025
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
The global single cell analysis market was valued at US$3,255.0 million in 2022 and is projected to grow at a CAGR of 15.1% during the forecast period 2022-2032.
The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.
The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet
The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
